Physician profile
Mark W Peller
NPI 1013905462
$4,093.47
in general payments reported to CMS, 2019-2025
10 companies · $466 in 2025
The $466 reported for 2025 was more than what 75% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $720 · 2020: $45.51 · 2021: $268 · 2022: $544 · 2023: $1,083 · 2024: $966 · 2025: $466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,516.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,515.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,736.27 | 2022-2025 | Infuse |
| Alcon Vision LLC | $814.82 | 2019-2025 | Total30, Dailies Total1, Precision7 |
| Coopervision INC. | $538.06 | 2023-2025 | Myday Contact Lens, Clariti Contact Lens, Misight Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $299.41 | 2019 | |
| Maculogix, INC. | $162.13 | 2019 | |
| Allergan, INC. | $147.02 | 2021-2022 | |
| Sight Sciences, INC. | $117.13 | 2022 | |
| Johnson & Johnson Vision Care, INC. | $97.47 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $90.73 | 2024 | Xdemvy |
| Topcon Healthcare, INC. | $90.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Peller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.